World's Best Scientists 2026 revealed!
Award Badge
Biology and Biochemistry
Germany
2026
Award Badge
Medicine
Germany
2026

D-Index & Metrics

Biology and Biochemistry

D-Index
144
Citations
94101
World Ranking
226
National Ranking
14

Medicine

D-Index
156
Citations
125211
World Ranking
901
National Ranking
43

Hans-Peter Hartung publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Hans-Peter Hartung sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 1,165 publications — 100th percentile

100% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Hans-Peter Hartung D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Hans-Peter Hartung sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 144 D-Index — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Biology and Biochemistry in Germany Leader Award
  • 2026 - Research.com Medicine in Germany Leader Award
  • 2025 - Research.com Biology and Biochemistry in Germany Leader Award
  • 2023 - Research.com Medicine in Germany Leader Award

Overview

Hans-Peter Hartung is affiliated with Heinrich Heine University Düsseldorf in Germany. Their research primarily spans the field of Medicine, with a focus on several subfields including Pathology and Forensic Medicine, Neurology, Oncology, Rheumatology, and Immunology.

The scientist's work is concentrated on key research topics such as Multiple Sclerosis Research Studies, Peripheral Neuropathies and Disorders, Neuroinflammation and Neurodegeneration Mechanisms, Rheumatoid Arthritis Research and Therapies, Cytokine Signaling Pathways and Interactions, Systemic Sclerosis and Related Diseases, and Immunotherapy and Immune Responses.

Frequent co-authors collaborating with Hans-Peter Hartung include Orhan Aktaş, Xavier Montalbán, Friedemann Paul, Bruce Cree, and Peter A. Calabresi.

Hans-Peter Hartung has published extensively in notable scientific venues. Regular publication venues include The Lancet Neurology, Brain, Multiple Sclerosis Journal, Neurology, and EBioMedicine.

Recent papers by Hans-Peter Hartung include:

  • "APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies" (2021) in Neurology
  • "Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial" (2020) in The Lancet Neurology
  • "Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial" (2020) in The Lancet Neurology
  • "The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history" (2020) in Brain
  • "Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study" (2021) in Multiple Sclerosis Journal

Best Publications

  • Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis

    W. Ian McDonald;Alistair Compston;Gilles Edan;Donald E Goodkin

  • Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

    Alan J. Thompson;Brenda L. Banwell;Frederik Barkhof;Frederik Barkhof;William M. Carroll

  • Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

    Chris H. Polman;Stephen C. Reingold;Gilles Edan;Massimo Filippi

  • Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

    Stephen Sawcer;Garrett Hellenthal;Matti Pirinen;Chris C. A. Spencer

  • Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

    Jeffrey A. Cohen;Frederik Barkhof;Giancarlo Comi;Hans Peter Hartung

  • Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

    Xavier Montalban;Stephen L. Hauser;Ludwig Kappos;Douglas L. Arnold

  • Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

    Giancarlo Comi;Massimo Filippi;Frederik Barkhof;Luca Durelli

  • Guillain–Barré Syndrome

    Nobuhiro Yuki;Hans-Peter Hartung

  • Chemotherapy-induced peripheral neuropathy.

    Stefan Quasthoff;Hans Peter Hartung

  • Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

    Jeffrey A. Cohen;Alasdair J. Coles;Douglas L. Arnold;Christian Confavreux

  • Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial

    Alasdair J. Coles;Cary L. Twyman;Douglas L. Arnold;Jeffrey A. Cohen

  • Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.

    Hans-Peter Hartung;Richard Gonsette;Nikolaus Konig;Hubert Kwiecinski

  • Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds

    Franz Fazekas;Reinhold Kleinert;Gudrun Roob;Gertrude Kleinert

  • ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

    X. Montalban;R. Gold;A. J. Thompson;S. Otero‐Romero

  • Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques.

    R Gold;M Schmied;G Giegerich;H Breitschopf

  • Electrophysiological classification of guillain-barré syndrome: Clinical associations and outcome

    R. D. M. Hadden;D. R. Cornblath;R. A. C. Hughes;J. Zielasek

  • Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis

    Jerold Chun;Hans-Peter Hartung

  • Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome

    Rac Hughes;AV Swan;Cornblath;HP Hartung

  • Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)

    Dawn Langdon;M P Amato;J Boringa;B Brochet

  • Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

    L. Kappos;C.H. Polman;M.S. Freedman;G. Edan

Frequent Co-Authors

Bernd C. Kieseier
Bernd C. Kieseier Novartis (Switzerland)
Orhan Aktas
Orhan Aktas Heinrich Heine University Düsseldorf
Ludwig Kappos
Ludwig Kappos University Hospital of Basel
Xavier Montalban
Xavier Montalban Autonomous University of Barcelona
Bernhard Hemmer
Bernhard Hemmer Technical University of Munich
Eva Havrdova
Eva Havrdova Charles University
Krzysztof Selmaj
Krzysztof Selmaj University of Warmia and Mazury in Olsztyn
Douglas L. Arnold
Douglas L. Arnold Montreal Neurological Institute and Hospital
Giancarlo Comi
Giancarlo Comi Vita-Salute San Raffaele University
Olaf Stüve
Olaf Stüve The University of Texas Southwestern Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Biology and Biochemistry in the USA opens doors to a wide range of careers in healthcare and research. Many students choose to expand their expertise with flexible education options, like a cheap online MBA healthcare administration program. This degree can boost leadership opportunities in medical and pharmaceutical organizations.

Another pathway is medical coding, which plays a vital role in healthcare. Salary expectations for this field are appealing, as detailed in this overview of medical coding salary benchmarks. Getting certified is important; candidates often debate ccs vs cpc certification to determine which is best for their career trajectory and earning potential.

If you’re interested in allied health, understanding the medical coding job outlook is crucial. The demand for skilled billers and coders is strong, offering job security and diverse work environments. These pathways complement biology and biochemistry backgrounds, providing practical and rewarding career options beyond the lab.

Best Scientists Citing Hans-Peter Hartung

Trending Scientists

Recently Published Articles